Effect of 3-month therapy with empagliflozin on ambulatory blood pressure and arterial stiffness in patients with type 2 diabetes mellitus.
作者信息
Papazafiropoulou Athanasia K, Mpoumi Louisa, Papantoniou Styliani, Rallatou Maria, Antonopoulos Stavros, Melidonis Andreas
机构信息
First Department of Internal Medicine, Diabetes Center, Tzaneio General Hospital of Piraeus, Piraeus, Greece.
Diabetes and Cardiometabolic Center, Metropolitan Hospital, Piraeus, Greece.
出版信息
Ann Afr Med. 2021 Apr-Jun;20(2):154-155. doi: 10.4103/aam.aam_19_20.
Abstract
摘要
相似文献
1
Effect of 3-month therapy with empagliflozin on ambulatory blood pressure and arterial stiffness in patients with type 2 diabetes mellitus.恩格列净治疗3个月对2型糖尿病患者动态血压和动脉僵硬度的影响。
Ann Afr Med. 2021 Apr-Jun;20(2):154-155. doi: 10.4103/aam.aam_19_20.
2
How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.恩格列净如何改善 2 型糖尿病患者的动脉僵硬度？临床试验的亚组分析。
Cardiovasc Diabetol. 2019 Mar 29;18(1):44. doi: 10.1186/s12933-019-0839-8.
3
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.恩格列净对2型糖尿病患者血压、动脉僵硬度标志物及血管阻力的影响。
Diabetes Obes Metab. 2015 Dec;17(12):1180-93. doi: 10.1111/dom.12572. Epub 2015 Oct 9.
4
Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus.恩格列净联合二甲双胍治疗改善 1 型糖尿病患者的动脉功能。
Cardiovasc Diabetol. 2018 Dec 3;17(1):153. doi: 10.1186/s12933-018-0797-6.
5
Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes.恩格列净和利拉利汀联合改善 2 型糖尿病患者的血压和血管功能。
Eur Heart J Cardiovasc Pharmacother. 2020 Nov 1;6(6):364-371. doi: 10.1093/ehjcvp/pvz078.
6
Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.将二肽基肽酶-4 抑制剂转换为钠-葡萄糖共转运蛋白 2 选择性抑制剂托格列净可改善 2 型糖尿病患者的动脉僵硬度：一项初步研究。
Curr Vasc Pharmacol. 2019;17(4):411-420. doi: 10.2174/1570161116666180515154555.
7
Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.胰高血糖素样肽-1 受体激动剂、钠-葡萄糖共转运蛋白-2 抑制剂及其联合应用对 2 型糖尿病患者内皮糖萼、动脉功能和心肌做功指数的影响：12 个月治疗后的结果。
J Am Heart Assoc. 2020 May 5;9(9):e015716. doi: 10.1161/JAHA.119.015716. Epub 2020 Apr 24.
8
Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment.胰高血糖素样肽-1 受体激动剂和钠-葡萄糖共转运蛋白 2 抑制剂对伴有肾功能损害的 2 型糖尿病患者的影响。
Diab Vasc Dis Res. 2020 Nov-Dec;17(6):1479164120971220. doi: 10.1177/1479164120971220.
9
Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.钠-葡萄糖协同转运蛋白2抑制剂对血压的影响。
Vasc Health Risk Manag. 2016 Oct 27;12:393-405. doi: 10.2147/VHRM.S111991. eCollection 2016.
10
Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.恩格列净可降低 2 型糖尿病患者的血压和尿酸：系统评价和荟萃分析。
J Hum Hypertens. 2019 Apr;33(4):327-339. doi: 10.1038/s41371-018-0134-2. Epub 2018 Nov 15.
引用本文的文献
1
Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study.恩格列净和达格列净对伴有心血管合并症的 2 型糖尿病患者动态动脉僵硬度的影响：一项前瞻性观察研究。
Medicina (Kaunas). 2022 Aug 27;58(9):1167. doi: 10.3390/medicina58091167.
本文引用的文献
1
Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.恩格列净改善代谢综合征 ZSF1 大鼠的收缩压、内皮功能障碍和心脏重构。
Cardiovasc Diabetol. 2020 Feb 18;19(1):19. doi: 10.1186/s12933-020-00997-7.
2
Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes.恩格列净和利拉利汀联合改善 2 型糖尿病患者的血压和血管功能。
Eur Heart J Cardiovasc Pharmacother. 2020 Nov 1;6(6):364-371. doi: 10.1093/ehjcvp/pvz078.
3
SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects.SGLT2 抑制剂：对其降糖和心脏保护作用的评价。
Int J Environ Res Public Health. 2019 Aug 17;16(16):2965. doi: 10.3390/ijerph16162965.
4
How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.恩格列净如何改善 2 型糖尿病患者的动脉僵硬度？临床试验的亚组分析。
Cardiovasc Diabetol. 2019 Mar 29;18(1):44. doi: 10.1186/s12933-019-0839-8.
5
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.恩格列净对2型糖尿病患者血压、动脉僵硬度标志物及血管阻力的影响。
Diabetes Obes Metab. 2015 Dec;17(12):1180-93. doi: 10.1111/dom.12572. Epub 2015 Oct 9.
Zotero 插件